Methods of measurement for tumor mutational burden in tumor tissue.
暂无分享,去创建一个
Isabelle Salmon | Sandrine Rorive | Nicky D'Haene | S. Rorive | I. Salmon | B. Meléndez | M. Remmelink | Bárbara Meléndez | Myriam Remmelink | N. D’haene | C. Van Campenhout | Claude Van Campenhout
[1] Joshua F. McMichael,et al. Optimizing cancer genome sequencing and analysis. , 2015, Cell systems.
[2] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[3] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[4] M. Marton,et al. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories , 2016, International journal of molecular sciences.
[5] Emily H Turner,et al. Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.
[6] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[7] M. Berger,et al. Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Nikhil Wagle,et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.
[9] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[10] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[11] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[12] D. Carbone,et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .
[13] R. Salgia,et al. Value-based genomics , 2018, Oncotarget.
[14] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[16] Anne-Mette K. Hein,et al. Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue , 2014, PloS one.
[17] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[18] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[19] Jorge Sabbaga,et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.
[20] J. Carpten,et al. Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples , 2012, PloS one.
[21] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[22] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[23] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[24] A. Broomer,et al. Estimating tumor mutation burden using next-generation sequencing assay. , 2017 .
[25] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[26] Alexander Dobrovic,et al. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. , 2015, Clinical chemistry.
[27] S. Ramalingam,et al. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[29] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .